These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18477054)

  • 1. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
    Grey M
    Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
    Dilhuydy MS; Jouary T; Demeaux H; Ravaud A
    Br J Haematol; 2007 Jun; 137(6):490. PubMed ID: 17425643
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
    J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
    Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
    Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
    Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
    Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
    [No Abstract]   [Full Text] [Related]  

  • 6. Atypical presentation of varicella zoster in a patient on alemtuzumab.
    Venkatachalapathy S; Crowe J; Gray A
    Br J Haematol; 2007 Aug; 138(4):406. PubMed ID: 17659051
    [No Abstract]   [Full Text] [Related]  

  • 7. NCCN: New directions in chronic lymphocytic leukemia.
    O'Brien S
    Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553
    [No Abstract]   [Full Text] [Related]  

  • 8. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
    Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
    Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
    Pitini V; Arrigo C; Barresi G
    Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
    [No Abstract]   [Full Text] [Related]  

  • 14. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Byrd JC; Rai KR
    Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
    Boyd K; Dearden CE
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
    Thachil J; Salim R
    Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
    Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
    Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
    Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
    Oberoi SS; Abou Jawde RM
    J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
    [No Abstract]   [Full Text] [Related]  

  • 20. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
    Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
    Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.